ALLO vs. ARQT, GLPG, INDV, AKRO, DYN, IMCR, EVO, GPCR, TVTX, and VIR
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Arcutis Biotherapeutics (ARQT), Galapagos (GLPG), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Structure Therapeutics (GPCR), Travere Therapeutics (TVTX), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.
Allogene Therapeutics vs.
Allogene Therapeutics (NASDAQ:ALLO) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
Allogene Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
In the previous week, Arcutis Biotherapeutics had 10 more articles in the media than Allogene Therapeutics. MarketBeat recorded 17 mentions for Arcutis Biotherapeutics and 7 mentions for Allogene Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.50 beat Allogene Therapeutics' score of -0.06 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Allogene Therapeutics received 218 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 65.57% of users gave Allogene Therapeutics an outperform vote while only 65.26% of users gave Arcutis Biotherapeutics an outperform vote.
83.6% of Allogene Therapeutics shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Allogene Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Allogene Therapeutics' return on equity of -52.13% beat Arcutis Biotherapeutics' return on equity.
Arcutis Biotherapeutics has higher revenue and earnings than Allogene Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Allogene Therapeutics presently has a consensus target price of $9.73, suggesting a potential upside of 434.80%. Arcutis Biotherapeutics has a consensus target price of $16.60, suggesting a potential upside of 30.91%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Allogene Therapeutics is more favorable than Arcutis Biotherapeutics.
Summary
Allogene Therapeutics beats Arcutis Biotherapeutics on 13 of the 18 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 1/18/2025 by MarketBeat.com Staff
Free ALLO Stock Alerts